Ascletis Pharma Inc.
ASCLF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,283 | $56,596 | $54,090 | $76,876 |
| % Growth | -97.7% | 4.6% | -29.6% | – |
| Cost of Goods Sold | $548 | $30,606 | $78,782 | $37,703 |
| Gross Profit | $735 | $25,990 | -$24,692 | $39,173 |
| % Margin | 57.3% | 45.9% | -45.6% | 51% |
| R&D Expenses | $302,394 | $216,781 | $267,102 | $213,320 |
| G&A Expenses | $101,744 | $62,576 | $15,429 | $16,491 |
| SG&A Expenses | $101,744 | $62,963 | $32,414 | $37,363 |
| Sales & Mktg Exp. | $0 | $387 | $16,985 | $20,872 |
| Other Operating Expenses | -$107,984 | $46,454 | $19,770 | $13,456 |
| Operating Expenses | $296,154 | $326,198 | $319,286 | $264,139 |
| Operating Income | -$295,419 | -$300,208 | -$343,978 | -$224,966 |
| % Margin | -23,025.6% | -530.4% | -635.9% | -292.6% |
| Other Income/Exp. Net | -$5,517 | $155,493 | $29,135 | $25,949 |
| Pre-Tax Income | -$300,936 | -$144,715 | -$314,843 | -$199,017 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$300,936 | -$144,715 | -$314,843 | -$199,017 |
| % Margin | -23,455.7% | -255.7% | -582.1% | -258.9% |
| EPS | -0.3 | -0.13 | -0.29 | -0.18 |
| % Growth | -130.8% | 55.2% | -61.1% | – |
| EPS Diluted | -0.3 | -0.13 | -0.29 | -0.18 |
| Weighted Avg Shares Out | 1,001,589 | 1,074,111 | 1,087,030 | 1,097,608 |
| Weighted Avg Shares Out Dil | 1,001,589 | 1,074,103 | 1,087,030 | 1,097,608 |
| Supplemental Information | – | – | – | – |
| Interest Income | $91,993 | $99,278 | $44,162 | $22,506 |
| Interest Expense | $0 | $144 | $157 | $125 |
| Depreciation & Amortization | $14,183 | $18,480 | $30,191 | $29,545 |
| EBITDA | -$390,450 | -$126,091 | -$284,495 | -$169,347 |
| % Margin | -30,432.6% | -222.8% | -526% | -220.3% |